Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia
NCT ID: NCT00314288
Last Updated: 2017-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
360 participants
INTERVENTIONAL
2002-07-31
2003-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
NCT00105521
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
NCT00105508
Sarizotan in the Treatment of Neuroleptic-induced Tardive Dyskinesia
NCT00310661
EMD 128130 for the Treatment of Parkinson's Disease
NCT00009048
A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)
NCT01294800
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sarizotan HCl
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The subject is an out-patient
* Age 30 years or above
* Dyskinesias present during more than 25% of the waking day
* Dyskinesias at least moderately disabling
* Written informed consent
Exclusion Criteria
* Participation in another study within the last 30 days
* Dementia or other psychiatric illness that prevents provision of informed consent
* History of allergic disorders such as asthma
* Known hypersensitivity to the study treatment(s)
* Known hypersensitivity to ACTH
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
EMD Serono
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fountain Valley, California, United States
Sunnyvale, California, United States
Miami, Florida, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Augusta, Maine, United States
Boston, Massachusetts, United States
Kansas City, Missouri, United States
Brooklyn, New York, United States
New York, New York, United States
Cincinnati, Ohio, United States
Columbus, Ohio, United States
Philadelphia, Pennsylvania, United States
Pawtucket, Rhode Island, United States
Memphis, Tennessee, United States
Houston, Texas, United States
Leuven, , Belgium
Sofia, , Bulgaria
Edmonton, , Canada
Saskatoon, , Canada
Vancouver, , Canada
Clermont-Ferrand, , France
Marseille, , France
Nantes, , France
Paris, , France
Toulouse, , France
Bochum, , Germany
Dresden, , Germany
Leipzig, , Germany
Lübeck, , Germany
München, , Germany
Ulm, , Germany
Wiesbaden, , Germany
Budapest, , Hungary
Győr, , Hungary
Miskolc, , Hungary
Coimbra, , Portugal
Lisbon, , Portugal
Bucaresti, , Romania
Constanța, , Romania
Târgu Mureş, , Romania
George, , South Africa
Plumstead Cape Town, , South Africa
Rosebank, , South Africa
Sunninghill, , South Africa
Wilgers, , South Africa
Cambridge, , United Kingdom
Newcastle, , United Kingdom
Nottingham, , United Kingdom
Sheffield, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EMR 62225-006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.